Regulus Therapeutics Inc. Stock
Regulus Therapeutics Inc. Stock price
Key metrics
| Market capitalization | $542.80m |
| Enterprise Value | $479.37m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 7.53 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-51.75m |
| Free Cash Flow (TTM) Free Cash Flow | $-43.66m |
| Cash position | $65.43m |
Is Regulus Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,793 stocks worldwide.
Regulus Therapeutics Inc. Stock Analysis
Analyst Opinions
6 Analysts have issued a Regulus Therapeutics Inc. forecast:
Analyst Opinions
6 Analysts have issued a Regulus Therapeutics Inc. forecast:
Financial data from Regulus Therapeutics Inc.
| Mar '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.35 -0.35 |
35%
35%
|
|
| EBITDA | -51 -51 |
59%
59%
|
EBIT (Operating Income) EBIT | -52 -52 |
59%
59%
|
| Net Profit | -48 -48 |
51%
51%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Regulus Therapeutics Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Regulus Therapeutics Inc. Stock News
Company Profile
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.
| Head office | United States |
| CEO | Joseph Hagan |
| Employees | 34 |
| Founded | 2007 |
| Website | www.regulusrx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
